ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Cancer Center To Get Recommended Funding, Restoration of 1990-91 Cuts, NCI Tells Directors

July 24, 1992

NCCS Begins Program To Help Develop Survivors’ Care Plan

February 27, 2009

President Signs Supplemental Funding For NIH And FDA.

July 11, 2008

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

NCI Bypass Budget Calls For $5.98 Billion

December 6, 2002

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001